Recordati's Board of Directors approved the consolidated
financial statements for the year 2012 as well as Recordati S.p.A.'s
accounts
and the corporate governance and ownership report as required by art. 123
bis of
the Consolidated Law on Financial Intermediation. The financial
statements at
and for the year ended 31 December 2012 and the aforesaid report
will be
available as from tomorrow 8 March 2013 at the company's head
office and
published on the company's website www.recordati.com and will also be
available
on the website of Borsa Italiana S.p.A.. The reports issued by the
independent
and by the statutory Auditors will be made available, within the terms
of the
law, in the same manner.

Financial highlights

* Consolidated revenue in 2012 is EUR 828.3 million, up by 8.7% compared
to the
preceding year. Pharmaceutical sales are EUR 797.4 million, an
increase of
8.7% while pharmaceutical chemicals sales are EUR 30.9 million, an
increase of
8.9%.

* Operating income, at 20.2% of sales, is EUR 167.0 million, an
increase of
2.1% over the preceding year. Fourth quarter results include non-
recurring
costs related to the acquisition of the European rights to
Graspa® (EUR 5
million) and to the restructuring of our sales organization.

* Net income at 14.3% of sales is EUR 118.5 million, an increase of 1.8%.

* Net financial position* at 31 December 2012 records a net debt of EUR
153.5
million as compared to a net debt of EUR 55.7 million at 31 December
2011.
During the year EUR 21.0 million were paid for the acquisition of
six OTC
products in Germany, EUR 14.3 million overall were paid for the
acquisitions
in Poland of the pharmaceutical company Farma-Projekt plus a
portfolio of
products and EUR 66.7 million were paid for the acquisition of a
product
portfolio in Russia. Dividends for a total of EUR 61.4
million were
distributed.

* Cash and short-term financial investments net of bank overdrafts
and
medium/long-term loans which include the measurement at fair value of
hedging
derivatives (fair value hedge).

Business development news

A number of initiatives were pursued in 2012 which are fundamental
for the
future development of the Group.

* In February the activities for the preparation of a European
Phase III
clinical trial for REC 0482 (NX-1207), following the successful
completion
of a Scientific Advice meeting with the European Medicines Agency (EMA)
were
initiated. The pivotal controlled clinical trial will assess the
efficacy
and safety of a single TRUS-guided intraprostatic injection of the
drug in
patients with lower urinary tract symptoms (LUTS) associated with
BPH not
adequately controlled by medical therapy. A European licensing
agreement for
the development and commercialization of NX-1207 was signed in
2010 by
Recordati and Nymox Pharmaceutical Corporation. Under the terms
of the
agreement Recordati received exclusive rights to develop and
subsequently
market and sell the drug in Europe including Russia and the CIS, the
Middle
East, South Africa and the Maghreb area of North Africa.

* During April the marketing authorizations, the trademarks and
additional
assets concerning six OTC pharmaceuticals for Germany were acquired
from
Cilag GmbH International and McNeil GmbH & Co. oHG. The products
acquired
are JHP-Rödler® (mint oil indicated for digestive disorder,
headache, cough
and cold), Betadorm® D (diphenhydramine HCl indicated for sleep
disorders),
Rhinopront® (pseudoephedrine+triprolidine indicated for rhinitis
and head
colds), Collomack® Topical (salicylic acid solution, an
anti-corn
preparation), Tirgon® (bisacodyl for constipation) and
Xitix® (vitamin C
lozenges to treat vitamin C deficiency). In 2012 the annual sales
for the
six products are of around EUR 6 million.

* In August the acquisition of 100% of the share capital of Farma-
Projekt Sp.
z o.o., a Polish pharmaceutical company with headquarters in
Krakow, was
concluded. The value of the transaction (enterprise value) is of PLN
71.0
million (EUR 17.4 million) of which PLN 50.8 million (EUR 12.5
million) were
paid at the closing. Of the remaining balance a portion will be
paid in
tranches on future dates and a portion comprises the company's debt.
Farma-Projekt operates on the Polish pharmaceutical market since 2003 and
markets
drugs belonging to a variety of therapeutic areas, mainly
cardiovascular and
urological treatments as well as dietary supplements. The company
employs
around 135 personnel, of which 84 are dedicated to sales and
marketing.
Sales in 2011 were of around PLN 47 million (EUR 11.5 million).

* In October the oral care line of products bearing the Dentosan®
trademark
was acquired for the Italian market from Cilag GmbH International,
part of
the Johnson & Johnson Family of Consumer Companies. Dentosan® is
the second
leading brand in the Italian oral care market at pharmacy level
(IMS -
September 2012). The line consists of three product categories:
mouthwash,
toothpaste gel and toothbrushes, sold mainly in pharmacies, and of
which the
mouthwash category represents the most important franchise. All
Dentosan®
mouthwash brands - Dentosan® Azione Intensiva, Dentosan®
Trattamento Mese
and Dentosan® Ortodontico - are based on chlorhexidine at
different
concentrations and are highly appreciated by the professional
dental
community and consumers. Recordati is a very well-known name in the
pharmacy
and we are confident that this prestigious brand will become even
more
popular in the future.

* In November the acquisition of all rights to five product lines
on the
Russian market: Alfavit, Qudesan, Vetoron, Focus and Carnitone
was
successfully concluded. The value of the transaction is of RUB 2.7
billion
(EUR 67.2 million). The brands of the products acquired, which
are OTC
pharmaceuticals and dietary supplements, are very well known in
Russia. The
Alfavit product line in particular comprises a wide range of
formulations
containing vitamins and minerals and holds a leading position on the
market.
Qudesan is based on coenzyme Q(10), an adjuvant for cardiac
function,
promoted for the prevention and treatment of chronic fatigue and
metabolic
dysfunction. The key ingredient in Vetoron is beta-carotene, Focus
contains
bilberry anthocyanins and lutein for eye health and Carnitone is a
source of
L-carnitine. Total annual sales of the five product lines are of
around RUB
1.0 billion (EUR 25 million).

* Also in November subsidiary Orphan Europe and Erytech Pharma, a
French
biopharmaceutical company, entered into an agreement granting Orphan
Europe
the exclusive rights for the commercialization and distribution of
Graspa®
for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute
Myeloid
Leukemia (AML) in Europe. Graspa®, human erythrocytes
encapsulating
L-asparaginase, for the treatment of hematological malignancies, is
currently
in pivotal Phase II/III clinical trial for ALL and will enter a
Phase IIb
trial in AML in Europe. The product has obtained an orphan drug
designation
in Europe and the USA for ALL. Graspa® is a new
formulation of
L-asparaginase with a safer and broader range of clinical use than
existing
forms due to the entrapment and protection of the enzyme inside
homologous
red blood cells. The added value of Graspa® (by encapsulating L-
asparaginase
in red blood cells) relates to its ability to overcome existing
limitations
associated with conventional L-asparaginase via longer efficacy,
better
compliance, reduced doses and a better safety profile. Graspa®
is intended
to satisfy the unmet medical needs of frail patients, patients
suffering
relapses and other patient groups for whom the current treatments
are not
suitable.

* In December an agreement for the acquisition of all rights
concerning a
portfolio of products indicated for the treatment of rare and other
diseases
and marketed mainly in the United States of America, from Lundbeck
LLC. was
signed. The value of the transaction, which was successfully
closed in
January 2013 is of $ 100 million. Expected revenues in 2013
for the
acquired portfolio are of around $ 40 million. The acquired portfolio
will
be marketed in the U.S. by Recordati Rare Diseases, a wholly-owned
U.S.
corporation. The main product in the portfolio is Panhematin®
(haemin for
injection) for the amelioration of recurrent attacks of acute
intermittent
porphyria. Other important drugs acquired are NeoProfen®
(ibuprofen lysine
injection) and Indocin® I.V. (indomethacin injection), indicated
to close a
clinically significant patent ductus arteriosus (PDA) in premature
infants,
and Cosmegen® (dactinomycin for injection) used mainly in the
treatment of
three rare cancers. The acquisition of this portfolio of products
is a
confirmation of Recordati's intention to become a leading player in
rare
diseases worldwide and will also contribute to the growth and
enhancement of
our current operation in the U.S..

Subsequent events and business outlook

Group consolidated sales during the first two months of 2013 are in line
with
the company's expectations for the whole year. For 2013, targets are to
achieve
sales of more than EUR 920 million, operating income of more than EUR
185 million
and net income of more than EUR 128 million. Objectives in the business
plan are
to achieve sales of between EUR 1.025 and EUR 1.075 million, operating
income of
between EUR 210 and EUR 220 million and net income of between EUR 140
and EUR 150
million in 2015.

Dividend

Based on the results obtained, the Board of Directors of the parent company
will
propose to the shareholders a dividend of EUR 0.10 per share, in full
balance of
the interim 2012 dividend of EUR 0.20, to be paid to all shares outstanding
at
ex-dividend date, excluding those in treasury stock, as from 25 April
2013 and
record date on 24 April 2013, with ex-dividend on 22 April 2013. The full
2012
dividend is therefore of EUR 0.30 per share (EUR 0.30 per share last
year).

Further Board resolutions

The Board of Directors approved the following deliberation proposals
to be
submitted to the Annual Meeting of Shareholders:
* the renewal of the authorization to buy back and dispose of Recordati
shares
until the Annual Shareholders' Meeting which will approve the 2013
financial
statements;

* the examination of the Remuneration Policy pursuant to article 123-
ter of
Legislative Decree 58/98;

* the approval of Shareholders' Meeting regulations.

The objective of the proposal to renew the authorization to buy back and
dispose
of Recordati shares until the Annual Shareholders' Meeting which will
approve
the 2013 financial statements is, as in previous years, to grant the
Board the
possibility: of using shares for equity acquisitions or as
consideration for
strategic agreements; of allowing the company to invest in its own
shares; and
of constituting a stock of own shares to service current and future stock
option
plans. The company would be allowed to purchase up to 20,000,000
Recordati
existing ordinary (common) shares, which includes those shares held in
Treasury
stock at any given time, for a maximum cash outlay of EUR 150,000,000
million.
The purchase price must be at least equal to the shares' nominal
value (EUR
0.125) and must not exceed the average official Stock Exchange price
recorded
over the 5 trading days prior to the transaction, plus 5%. Possible
purchases
will be made on regulated markets and must comply with article
132 of
Legislative Decree 58/1998 and with article 144-bis, comma 1.b) of the
Issuers'
Regulations as approved by CONSOB's resolution 11971/1999 and with
market
practice allowed and recognized by CONSOB. At 7 March 2013 the
company has
8,225,790 shares in Treasury stock which amounts to 3.9334% of the current
share
capital.

The Board of Directors also approved the Remuneration Report pursuant to
article
123-ter of the Legislative Decree 58/98, the first part of which
is the
Remuneration Policy to be submitted to the Annual Shareholders'
Meeting. The
Remuneration Report will be made available to the public within the terms
of the
law.

The Board of Directors also resolved to submit to the Shareholders'
Meeting the
approval of a Shareholders' Meeting Regulation, in compliance with
the
provisions of the Corporate Governance code. Further information
will be
provided in the Directors' report which will be made available at the
company's
head office and published on the company's website within the terms of law.

Call to an Annual Shareholders' Meeting

The Board of Directors resolved to convene the Annual Shareholders'
Meeting to
be held at the company's offices on 17 April 2013 at 10.00 am, the
sole
convocation date, with the following agenda:

3. Authorization proposal to buy back and dispose of Recordati shares;
inherent
and consequent resolutions.

4. Proposal to approve a Shareholders' Meeting regulation.
The convocation notice and the documents relative to the agenda
will be
published in the manner required and within the terms prescribed by current
laws
and regulations.

Recordati, established in 1926, is a European pharmaceutical group,
listed on
the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM,
ISIN IT
0003828271), with a total staff of over 3,300, dedicated to the
research,
development, manufacturing and marketing of pharmaceuticals.
Headquartered in
Milan, Italy, Recordati has operations in the main European
countries, in
Central and Eastern Europe, and in Turkey. A field force of more than
1,700
medical representatives promotes a wide range of innovative
pharmaceuticals,
both proprietary and under license, in a number of therapeutic areas
including a
specialized business dedicated to treatments for rare diseases. Recordati
is a
partner of choice for new product licenses from companies which do not
have a
European presence. Recordati is committed to the research and
development of
new drug entities within the cardiovascular and urogenital therapeutic
areas and
of treatments for rare diseases. Consolidated revenue for 2011 was EUR
762.0
million, operating income was EUR 163.5 million and net income was
EUR 116.4
million.

Statements contained in this release, other than historical facts, are
"forward-
looking statements" (as such term is defined in the Private
Securities
Litigation Reform Act of 1995). These statements are based on
currently
available information, on current best estimates, and on assumptions
believed to
be reasonable. This information, these estimates and assumptions may prove
to be
incomplete or erroneous, and involve numerous risks and uncertainties,
beyond
the Company's control. Hence, actual results may differ materially from
those
expressed or implied by such forward-looking statements. All
mentions and
descriptions of Recordati products are intended solely as information
on the
general nature of the company's activities and are not intended to
indicate the
advisability of administering any product in any particular instance.

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S
FINANCIAL
REPORTS

The manager responsible for preparing the company's financial reports
Fritz
Squindo declares, pursuant to paragraph 2 of Article 154-bis of the
Consolidated
Law on Finance, that the accounting information contained in this press
release
corresponds to the document results, books and accounting records.